Presenting at a prestigious annual meeting like ASGCT puts Sangamo Therapeutics in the spotlight, potentially increasing its stock value. The focus on neurology, a critical area in healthcare, along with advancements in gene therapy, could be seen as a positive indicator of the company's future success and its ability to lead in innovative treatments. This could lead to increased investor confidence and a positive short-term impact on SGMO's stock price.